Sofosbuvir + Ledipasvir

Janessa M. Smith, PharmD, BCPS
Sofosbuvir + Ledipasvir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

COVID-19 December 2020 Update: Therapies and VaccinesCOVID-19 December 2020 Update: Therapies and Vaccines

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Managing Sleep Problems during COVID-19Managing Sleep Problems during COVID-19

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection.
    • Indicated for treatment of HCV infection in treatment-experienced patients without cirrhosis and with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C)
    • Treatment-naïve patients with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C), and liver transplant recipients.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection.
    • Indicated for treatment of HCV infection in treatment-experienced patients without cirrhosis and with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C)
    • Treatment-naïve patients with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C), and liver transplant recipients.

There's more to see -- the rest of this entry is available only to subscribers.